Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.

Juergen Wolf,Edward B. Garon,Harry J.M. Groen,Daniel Shao-Weng Tan,I Gilloteau,Sylvie Le Mouhaër,Can Cai,Andrea Chassot Agostinho,Maria Reynolds,Dawn Odom,Rebecca S. Heist

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.

2021

Juergen Wolf
Edward B. Garon
Harry J.M. Groen
Daniel Shao-Weng Tan
I Gilloteau
Sylvie Le Mouhaër
Can Cai
Andrea Chassot Agostinho
Maria Reynolds
Dawn Odom
Rebecca S. Heist

9056Background: Capmatinib, a potent, selective MET inhibitor, showed substantial antitumor activity and manageable tolerability in patients with METex14-mutated advanced non-small cell lung cancer...

Keywords:

in patient
Tolerability
Medicine
non small cell
Internal medicine
Oncology
antitumor activity
Capmatinib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations